Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash & Equivalents (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Cash & Equivalents for 7 consecutive years, with $382.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 73.97% year-over-year to $382.5 million, compared with a TTM value of $382.5 million through Dec 2025, up 73.97%, and an annual FY2025 reading of $382.5 million, up 73.97% over the prior year.
  • Cash & Equivalents was $382.5 million for Q4 2025 at Avidity Biosciences, up from $350.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $575.8 million in Q2 2024 and bottomed at $85.6 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $274.4 million, with a median of $276.4 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents tumbled 64.95% in 2022, then skyrocketed 332.21% in 2024.
  • Year by year, Cash & Equivalents stood at $320.4 million in 2021, then grew by 6.23% to $340.4 million in 2022, then tumbled by 45.63% to $185.1 million in 2023, then increased by 18.79% to $219.9 million in 2024, then surged by 73.97% to $382.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for RNA at $382.5 million in Q4 2025, $350.2 million in Q3 2025, and $243.9 million in Q2 2025.